Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)
Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)
Not yet recruiting · NCT05778097 · Registry updated 2023-03-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study) | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Not yet recruiting | Phase 2 | 2023-03-21 | NCT05778097 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 164 |
| Xian-Janssen Pharmaceutical Ltd. | 6 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Nanjing First Hospital, Nanjing Medical University | Nanjing | China | 1 |
| Nanjing Tumor Hospital | Nantong | China | 1 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Nanjing | China | 12 |